News

ACQUISITION OF PHARMACEUTICAL PROFILES EXPANDS EARLY-PHASE DRUG DEVELOPMENT SERVICE OFFERING

admin — Mon, 15 Dec 2008 18:24:48 +0100

Newmarket, United Kingdom, December 15, 2008 – Quotient Bioscience Group Limited (“Quotient”), a leading European provider of analytical and safety evaluation services and products for bioscience and sport, is pleased to announce that it has acquired Pharmaceutical Profiles Group Limited (“Pharmaceutical Profiles”). Pharmaceutical Profiles will become an important member of Quotient’s Drug Development Services Group - Quotient Bioresearch.

Quotient Bioresearch completes a £4.5m investment to create 19,000 ft2 of new purpose built laboratories at its Fordham site

admin — Thu, 04 Dec 2008 10:58:22 +0100

CAMBRIDGE UK, 04 December 2008.
Quotient Bioresearch, a leading provider of early phase drug development and sports testing services, is pleased to announce the completion of a £4.5M, 19,000 ft2 laboratory build project at its Fordham site near Cambridge. Marking an important milestone in the growth of the company, this investment significantly expands Quotient Bioresearch’s facilities to create one of the largest laboratories of its type in the world.

NEXT GENERATION MASS SPECTROMETRY for METABOLITE IDENTIFICATION

admin — Fri, 07 Nov 2008 11:25:20 +0100

NEXT GENERATION MASS SPECTROMETRY for METABOLITE IDENTIFICATION

Cambridge, UK. (7 November 2008) Quotient Bioresearch, a leading provider of early phase drug development and sports testing services, today announces that it is investing in its development with the purchase of three Thermo Scientific LTQ Orbitrap™ XL mass spectrometers.This significant investment demonstrates Quotient Bioresearch’s commitment to offering the highest quality service to its customers.

QUOTIENT RECEIVES STRATEGIC INVESTMENT OF £35 MILLION From TA ASSOCIATES

admin — Thu, 18 Sep 2008 12:02:34 +0200

Proceeds to be used to fund aquisition-led and organic growth strategy.

QUOTIENT CONSOLIDATES DRUG DEVELOPMENT BUSINESSES

admin — Thu, 18 Sep 2008 11:57:53 +0200

Businesses now fully integrated and Quotient seeking further acquisitions

QUOTIENT BIORESEARCH ACQUIRES BIODYNAMICS RESEARCH LTD

admin — Thu, 18 Sep 2008 11:52:42 +0200

Further expansion for Quotient BioResearch in drug development services through the acquisition of BioDynamics Research, builds capacity and service offerings

ALBA BIOSCIENCE RECEIVES FDA CLEARANCE FOR MONOCLONAL BLOOD TYPING REAGENTS

admin — Thu, 18 Sep 2008 11:47:35 +0200

Edinburgh based Alba Bioscience has successfully received FDA clearance to manufacture 15 monoclonal blood typing reagents for supply into the US market. These ready-to-use reagents are critical for safe blood transfusion and include some unique products not previously available in the US.

QUOTIENT BIORESEARCH APPOINTS GORDON CAMERON AS CHIEF FINANCIAL OFFICER

admin — Thu, 18 Sep 2008 11:43:53 +0200

Quotient BioResearch Limited, the provider of analytical and safety evaluation services and products to the healthcare, pharmaceutical and biotechnology industries, is pleased to announce the appointment of Gordon Cameron, OBE as its new Chief Financial Officer.

QUOTIENT BIORESEARCH AQUIRES GRM HOLDINGS LTD

admin — Thu, 18 Sep 2008 11:34:40 +0200

Quotient BioResearch Limited, the provider of analytical and safety evaluation services and products to the healthcare, pharmaceutical and biotechnology industries, is pleased to announce that it has acquired 100% of the share capital of GRM Holdings Limited which includes G.R. Micro Ltd. ("GRM") and G.R. Micro Environmental Healthcare Ltd. (GRM-EH).

QUOTIENT BIORESEARCH AQUIRES ALBA BIOSCIENCE LIMITED

admin — Thu, 18 Sep 2008 11:03:38 +0200

Newmarket and Edinburgh, United Kingdom, August 31, 2007 – Quotient BioResearch Limited is pleased to announce that, together with management, it has acquired 100% of the business and assets of Alba Bioscience from the Scottish National Blood Transfusion Service.